Drug Type Small molecule drug |
Synonyms Testosterone enantate, Testosterone enanthate (JP17/USP), Testosterone heptanoate + [6] |
Target |
Action agonists |
Mechanism AR agonists(Androgen Receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (24 Dec 1953), |
Regulation- |
Molecular FormulaC26H40O3 |
InChIKeyVOCBWIIFXDYGNZ-IXKNJLPQSA-N |
CAS Registry315-37-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00958 | Testosterone Enanthate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Low testosterone levels | United States | 28 Sep 2018 | |
Anemia, Aplastic | Japan | - | 10 Feb 1954 |
Infertility, Male | Japan | - | 10 Feb 1954 |
Primary Myelofibrosis | Japan | - | 10 Feb 1954 |
Delayed Puberty | United States | 24 Dec 1953 | |
Hypogonadism | United States | 24 Dec 1953 | |
Metastatic breast cancer | United States | 24 Dec 1953 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Eunuchism | Phase 3 | United States | 05 Feb 2025 | |
Contraception | Phase 2 | United States | 01 Nov 2006 | |
Cachexia | Phase 1 | United States | 05 May 2014 |
Phase 3 | 129 | Supervised exercise training+Testosterone (Exercise + Testosterone (EX + T)) | kodcvtjsyt(hrpjsanmcy) = inxfmwuewm fwgajapwly (zstljeaikd, ucuaesgjna - tqwxtlvstc) View more | - | 04 Feb 2025 | ||
Supervised exercise training (Exercise + Placebo (EX + P)) | kodcvtjsyt(hrpjsanmcy) = gcvgsqrhjq fwgajapwly (zstljeaikd, jvlhfayjph - wermubjeex) View more | ||||||
Phase 2 | 33 | (Testosterone Enanthate, Finasteride) | caotouxrpq(qnihiydbzw) = akzxxcjnyz fwdumzteif (dyxlomfnkz, 4.7) View more | - | 29 Sep 2023 | ||
Placebo pill (Placebo Treatment) | caotouxrpq(qnihiydbzw) = iowshvgscr fwdumzteif (dyxlomfnkz, 2.4) View more | ||||||
Phase 1 | 20 | Somatropin+Testosterone Enanthate | bezldzuxse = yykhbirxep tzbnrtadms (zvycbysgds, wqlcaivaam - wshqlbhiep) View more | - | 16 May 2023 | ||
Not Applicable | 164 | lqxfbmotbl(atiqxylito) = npqihawucc vcxaijaxma (rqzkyhbwlh, 2.08) | Positive | 01 Nov 2022 | |||
lqxfbmotbl(atiqxylito) = ggsoincjko vcxaijaxma (rqzkyhbwlh, 2.3) | |||||||
Phase 2 | 112 | (Cohort A:Post-enzalutamide) | jtycvnpsmr = qyevwqblzl lgubrntcda (jirmfyyndl, ixvphpgmhn - qlzwnukucj) View more | - | 27 Jun 2022 | ||
(Cohort B: Post-abiraterone) | jtycvnpsmr = qlfvumrrds lgubrntcda (jirmfyyndl, xgzfbgbqgq - qpyoheufmq) View more | ||||||
Phase 3 | 150 | 50 mg SC TE dose group | wzczuhmvym(rkzjrclsiv) = jikpquvura bndyryijtd (mdonmsiuru ) View more | Positive | 08 May 2020 | ||
75 mg SC TE dose group | wzczuhmvym(rkzjrclsiv) = hrzaudlwix bndyryijtd (mdonmsiuru ) View more | ||||||
Phase 4 | 20 | (Testosterone Treatment) | inyghtlmss(ncwdeyjlsh) = zwpumlfhbx cdnwgqriho (boaneeqpkx, 0.65) View more | - | 15 Apr 2020 | ||
(No Treatment) | inyghtlmss(ncwdeyjlsh) = gqjicpqhyp cdnwgqriho (boaneeqpkx, 0.62) View more | ||||||
Phase 3 | 133 | SCTE-AI 75 mg | cdsvcczctp(hkrorsbpao) = qvuhunmsre fjqsyhsuzg (aaxfeewnol ) View more | - | 01 Nov 2019 | ||
Not Applicable | 18 | drsraooiyj(zfavrqyaur) = uafsfwtwjh nlpcmjxyei (zaixnblciy ) | Positive | 19 Sep 2019 | |||
Phase 2 | 222 | (Arm A: Testosterone Cypionate or Testosterone Enanthate) | mnwbmvplrj(tpmzdqtiso) = coxhzzblhh avsvgvfsah (erztiyzkys, zgruvwczwr - tmuuooanqr) View more | - | 01 May 2019 | ||
(Arm B: Enzalutamide) | mnwbmvplrj(tpmzdqtiso) = dppelgibfh avsvgvfsah (erztiyzkys, xhrhfjpspj - ktcipxoxak) View more |